Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.21.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
June 30, 2021 December 31, 2020
Current pharma contract assets (1)
$ 1,842  $ 1,643 
Long-term pharma contract assets (2)
325  290 
Total pharma contract assets $ 2,167  $ 1,933 
Current pharma capitalized commissions (1)
$ 128  $ 185 
Long-term pharma capitalized commissions (2)
940  970 
Total pharma capitalized commissions $ 1,068  $ 1,155 
Current pharma contract liabilities $ 4,497  $ 4,029 
Long-term pharma contract liabilities (3)
794  712 
Total pharma contract liabilities $ 5,291  $ 4,741 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2021 2020 2021 2020
Clinical Services:
    Client direct billing $ 63,137  $ 45,244  $ 123,846  $ 99,535 
    Commercial Insurance 20,528  15,148  39,102  37,142 
    Medicare and Medicaid 17,484  13,541  34,634  30,024 
    Self-Pay 256  (49) 310  165 
Total Clinical Services $ 101,405  $ 73,884  $ 197,892  $ 166,866 
Pharma Services: 20,319  13,093  39,365  26,141 
Total Revenue $ 121,724  $ 86,977  $ 237,257  $ 193,007